Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Rutherford Diagnostics recently spoke alongside the Secretary of Health and Social Care, Matt Hancock, at Insider's Health Innovation Conference in Manchester on 25 April.
The Northern Powerhouse has been hailed as being a "big part" of the success the UK has had in establishing itself as a world leader in pharmaceuticals, medical technologies and digital health. Secretary, Matt Hancock also outlined why some of the "most dynamic growth and exciting innovation" is going to happen across the region in the coming years.
Our Rutherford Diagnostics Chief Diagnostic Officer, Steve Powell, spoke alongside Hancock and other leaders who have been praised for leading innovation in healthcare. Hancock went on to discuss why working together to change the future landscape of healthcare is so important.